Pretreatment CT-derived body composition adds prognostic value beyond clinical-inflammatory factors in esophageal squamous cell carcinoma: a two-center retrospective development and external validation study

CT-derived body composition is associated with outcomes in esophageal cancer, but its added value beyond routine pretreatment risk assessment remains uncertain. We evaluated whether pretreatment L3 body composition improves survival prediction beyond a prespecified clinical-inflammatory model in ESCC treated with definitive concurrent chemoradiotherapy. This retrospective two-center study included 296 patients with nonmetastatic ESCC (development, n = 201; external validation, n = 95). Skeletal muscle index (SMI), skeletal muscle radiation attenuation (SMRA), visceral-to-subcutaneous adipose tissue ratio (VAT/SAT), and intermuscular adipose tissue index (IMATI) were measured on portal venous phase CT at L3. A clinical-inflammatory reference model (Model A) was compared with Model B, which added the four CT measures. Cox models underwent 1000-resample bootstrap internal validation and locked external validation without refitting or recalibration. In development, Model B increased the optimism-corrected C-index from 0.606 to 0.659 (difference, 0.053; 95% CI, 0.020–0.091) and 3-year AUC from 0.672 to 0.751. In external validation, the C-index increased from 0.657 to 0.721 (difference, 0.063; 95% CI, 0.017–0.116) and 3-year AUC from 0.690 to 0.772 (difference, 0.082; 95% CI, 0.015–0.192). The 3-year Brier score improved from 0.221 to 0.185. External calibration slope was 1.17, with modest mortality overprediction (55.7% predicted vs. 49.2% observed). SMRA showed the strongest individual imaging association with mortality. Pretreatment CT-derived body composition improved survival prediction beyond clinical-inflammatory factors in ESCC, and the improvement was maintained in regional external validation. Broader multicenter validation is required before clinical implementation.

Authors

Institutions

Publication Details

Journal
Cancer Imaging
Published
2026-11-12
DOI
https://doi.org/10.1186/s40644-026-01159-w
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pretreatment CT-derived body composition adds prognostic value beyond clinical-inflammatory factors in esophageal squamous cell carcinoma: a two-center retrospective development and external validation study

Shaobo Fang, Dan Li, Yiyang Yan, Tao Wang
Cancer Imaging
Esophageal Cancer Research and Treatment
article

Pretreatment CT-derived body composition adds prognostic value beyond clinical-inflammatory factors in esophageal squamous cell carcinoma: a two-center retrospective development and external validation study

Shaobo Fang, Dan Li, Yiyang Yan, Tao Wang
article en

Abstract

CT-derived body composition is associated with outcomes in esophageal cancer, but its added value beyond routine pretreatment risk assessment remains uncertain. We evaluated whether pretreatment L3 body composition improves survival prediction beyond a prespecified clinical-inflammatory model in ESCC treated with definitive concurrent chemoradiotherapy. This retrospective two-center study included 296 patients with nonmetastatic ESCC (development, n = 201; external validation, n = 95). Skeletal muscle index (SMI), skeletal muscle radiation attenuation (SMRA), visceral-to-subcutaneous adipose tissue ratio (VAT/SAT), and intermuscular adipose tissue index (IMATI) were measured on portal venous phase CT at L3. A clinical-inflammatory reference model (Model A) was compared with Model B, which added the four CT measures. Cox models underwent 1000-resample bootstrap internal validation and locked external validation without refitting or recalibration. In development, Model B increased the optimism-corrected C-index from 0.606 to 0.659 (difference, 0.053; 95% CI, 0.020–0.091) and 3-year AUC from 0.672 to 0.751. In external validation, the C-index increased from 0.657 to 0.721 (difference, 0.063; 95% CI, 0.017–0.116) and 3-year AUC from 0.690 to 0.772 (difference, 0.082; 95% CI, 0.015–0.192). The 3-year Brier score improved from 0.221 to 0.185. External calibration slope was 1.17, with modest mortality overprediction (55.7% predicted vs. 49.2% observed). SMRA showed the strongest individual imaging association with mortality. Pretreatment CT-derived body composition improved survival prediction beyond clinical-inflammatory factors in ESCC, and the improvement was maintained in regional external validation. Broader multicenter validation is required before clinical implementation.

Cancer Imaging
Zhengzhou University (CN), Henan Provincial People's Hospital (CN)
Henan Provincial Science and Technology Research Project
Good health and well-being
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon